SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus) prior authorization at Elevance Health
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Elevance Health requires GLP-1 Receptor Agonist prior-authorization documentation for SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
Elevance Health reviews SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus) prior authorizations against its medical policy for GLP-1 Receptor Agonist. Elevance Health-specific context: Operates Anthem BCBS in 14 states. Owns Carelon (formerly AIM) which manages utilization for specialty drugs and advanced imaging. State complaint route is to the state insurance department where the policy was issued.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in GLP-1 Receptor Agonist
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Elevance Health's medical policy URL referenced in the cover letter
Elevance Health's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Step therapy
- Medical necessity for biologics
- Out-of-network for behavioral health
- Bariatric surgery prior auth
SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus)-specific denial patterns and context
Across payers (not just Elevance Health), SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Weight-loss exclusion (Wegovy)
- Step therapy requiring oral semaglutide before injectable
- BMI threshold above FDA label
- Non-formulary tier 4 specialty
Sold as Ozempic (T2D), Wegovy (weight loss + CV risk reduction), Rybelsus (oral T2D). Wegovy received FDA CV indication March 2024 based on SELECT trial.
Manufacturer patient-assistance program: NovoCare — relevant when an Elevance Health denial sticks and the patient needs bridge access while appealing.
How Elevance Health approaches GLP-1 receptor agonists PAs
Elevance Health's GLP-1 receptor agonists reviewer typically anchors SEMAGLUTIDE (WEGOVY) prior-auth decisions on step therapy. Pharmacy-benefit review for SEMAGLUTIDE (WEGOVY) at Elevance Health is routed through CarelonRx (utilization management via Carelon, formerly AIM Specialty Health). The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 180-day internal-appeal window begins from the denial date. Plans including Elevance Health commonly distinguish T2D-indication PAs (Ozempic, Mounjaro, Trulicity) from weight-management-indication PAs (Wegovy, Zepbound, Saxenda) — the second path triggers benefit-exclusion review under the plan's anti-obesity-medication carve-out language. Elevance Health is domiciled in IN, so unresolved appeals escalate to the IN insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). Operates Anthem BCBS in 14 states.
If the PA is denied
Elevance Health gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://providers.anthem.com) with the same packet plus a peer-reviewed citation supporting SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal an Elevance Health denial on DenialHelp.
Contact Elevance Health
- Provider portal: https://providers.anthem.com
Frequently asked questions
What documentation does Elevance Health need for SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus) prior auth?
Elevance Health's typical PA packet for SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For GLP-1 Receptor Agonist, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Elevance Health?
Standard SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus) PA decisions at Elevance Health: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Elevance Health most often reject SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus) for?
Across Elevance Health's book the common rejection patterns include: Step therapy; Medical necessity for biologics; Out-of-network for behavioral health. For SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
Why does Elevance Health require specific BMI documentation for SEMAGLUTIDE (WEGOVY)?
Elevance Health's GLP-1 prior-auth policy distinguishes T2D-indication submissions (A1C-based criteria) from weight-management-indication submissions (BMI ≥30, or ≥27 with weight-related comorbidity, matching the FDA label). For weight-management SEMAGLUTIDE (WEGOVY) the reviewer also screens for the plan's anti-obesity-medication exclusion — submit the chart note with BMI, weight-related comorbidity (HTN, dyslipidemia, T2D, OSA, OA), and either (a) ≥6 months of documented lifestyle intervention or (b) a documented reason intensive lifestyle was inappropriate. 30-day standard decision, 180-day appeal window. Pharmacy-benefit handling is routed through CarelonRx (utilization management via Carelon, formerly AIM Specialty Health). External-review escalation for Elevance Health fully-insured policies sits with the IN insurance department.
How do I prep for a peer-to-peer with Elevance Health on SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus) PA packet
Open ApprovalHelp — generate a SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus) prior-auth packet tailored to Elevance Health's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com